Stopping Ozanimod: Large Trial Follow-Up Finds Relapses Return Mildly, With No Sign of Rebound
A large post hoc analysis of the DAYBREAK trial found that only 3.3 percent of patients relapsed after stopping ozanimod, ...
Tag: natalizumab
After Natalizumab: Real-World Study Pits Two B-Cell Drugs Head to Head in Multiple Sclerosis
A retrospective real-world study from Milan's San Raffaele institute compares ocrelizumab and ofatumumab as successor therapies for multiple sclerosis patients ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!